PharmAla Secures Supply Contract for Clinical Trials
PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTC:MDXXF) is making notable strides in the biotechnology field by partnering with Johns Hopkins Medicine to supply LaNeo™ MDMA for a significant clinical trial. This collaboration highlights PharmAla's vital involvement in the research and development of MDXX class molecules, reflecting their dedication to advancing medical science.
Dedication to Quality and Service
PharmAla's CEO, Nicholas Kadysh, underlines their commitment to offering exceptional service and top-quality investigational drug products to researchers across the globe. He points out that PharmAla is uniquely positioned to deliver GMP MDMA that meets the rigorous regulatory standards set by organizations such as the FDA. This dedication reaffirms PharmAla's standing in the industry as a reliable partner in MDMA supply.
A New Resource for Researchers
PharmAla has launched a new platform that provides researchers with comprehensive information regarding the quality of their drug products. By offering direct insights, PharmAla aims to streamline the process for researchers transitioning their clinical trial registrations and IRB approvals into an effective LaNeo MDMA Chemistry, Manufacturing, and Control package. This innovative approach reflects the company's commitment to supporting the ongoing advancement of clinical trials.
Updates on Corporate Developments
In its latest corporate update, PharmAla announced the conclusion of its agreement with Red Light Holland, officially initiating termination procedures. This decision illustrates PharmAla’s agile strategy in managing partnerships that align with their broader strategic objectives.
Presentation at EBPS Workshop
Enhancing their profile within the academic community, PharmAla will be presenting at the upcoming European Behavioural Pharmacology Society (EBPS) Workshop. Their presentation, categorized as a “Hot Topic,” will include data on their proprietary molecule APA-01, showcasing its potential as a powerful entactogen with improved safety pharmacology compared to traditional MDMA. This initiative exemplifies PharmAla's ongoing commitment to research and development.
Dr. Harpreet Kaur, the Vice President of Research at PharmAla, expressed pride in this acknowledgment, highlighting the collaborative work with the Fantegrossi lab that has attracted considerable attention from academic peers.
About PharmAla Biotech Holdings Inc.
PharmAla Biotech Holdings Inc. is a leading biotechnology company focusing on the research, development, and manufacture of MDXX class molecules, including MDMA. Their mission includes addressing the global shortage of clinical-grade MDMA that is essential for trials while also fostering the creation of innovative therapeutic options. PharmAla is uniquely positioned as the only provider of clinical-grade MDMA available for patient use beyond clinical trials, marking an important milestone in the industry.
With a strong research and development team, PharmAla has achieved significant progress, evident from the completion of proof-of-concept studies on various intellectual property families, including their primary candidate, ALA-002. They adhere to a ‘regulatory first’ principle, emphasizing the importance of maintaining strong relationships with regulatory authorities to succeed in the psychedelics sector long-term.
For more inquiries, please reach out to:
Nicholas Kadysh
Chief Executive Officer
PharmAla Biotech Holdings Inc.
Email: press@PharmAla.ca
Phone: 1-855-444-6362
Website: www.PharmAla.ca
Frequently Asked Questions
What is the significance of PharmAla's contract with Johns Hopkins?
This contract highlights PharmAla's role in providing MDMA for clinical trials, reinforcing its dedication to delivering high-quality drug products.
How does PharmAla ensure the quality of its products?
PharmAla adheres to strict GMP standards and collaborates closely with regulatory bodies to maintain top-notch production processes.
What are the recent developments at PharmAla?
Recently, PharmAla concluded its agreement with Red Light Holland, showing their strategic approach to corporate partnerships.
What is APA-01?
APA-01 is PharmAla's innovative proprietary molecule currently being evaluated for its potential as a safer alternative entactogen to MDMA.
How can researchers access information about PharmAla's products?
Researchers can obtain detailed quality information via PharmAla's new online tool, which aids in preparing for their clinical trials.
